ZEB2 and non-small cell lung carcinoma: Next, the follow-up visit experiments were conducted for 60 months, and the analysis results indicated that NSCLC patients with low-expressed miR-6734-3p (P < 0.05, Figure 1(e)) and high-expressed ZEB2 (P < 0.05, Figure 1(f)) tended to have an unfavorable prognosis.